This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.
Name: RO7234292 (RG6042)Description: Intrathecal injectionType: Drug
RO7234292 (RG6042) Q8W RO7234292 (RG6042) Q16W
Description: The Columbia-Suicide Severity Rating Scale (C-SSRS) is a structured tool to assess suicidal ideation and behavior. Four constructs are measured: severity of ideation, intensity of ideation, behavior, and lethality of actual suicide attempts. Binary (yes/no) data are collected for 10 categories, and composite endpoints based on the categories are followed over time to monitor patient safety.Measure: Change From Baseline in Behavioral Findings, as Assessed by the Columbia-Suicide Time: Baseline, Every 8 Weeks or Every 16 Weeks, and End of Treatment (up to approximately 5 years)
Description: MoCA contains a series of basic assessments, including attention and visuospatial tasks. The total score ranges from 0−30, where lower scores indicate greater impairment.Measure: Change From Baseline in Cognition, using Montreal Cognitive Assessment (MoCA) Time: Baseline, Every 16 Weeks, End of Treatment (up to approximately 5 years)
There is one SNP
Upon completion of the inclusion visit, eligible patients will receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks (Q16W) by bolus intrathecal injection. --- Q16W ---